OPKO Health, Inc. $OPK Shares Sold by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. has reduced its stake in OPKO Health, Inc. by 21.6%, owning 2,741,986 shares after selling 755,420 shares in the first quarter.
• OPKO Health reported a loss per share of ($0.19) for the last quarter, missing estimates, and a revenue of $156.80 million, which was below expectations of $165.74 million.
• CEO Phillip Frost acquired 675,000 shares of OPKO Health for approximately $891,000, bringing his total ownership to 214,676,448 shares.

Charles Schwab Investment Management Inc. decreased its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 21.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,741,986 shares of the biotechnology company's stock after selling 755,420 shares during the period. Charles Schwab Investment Management Inc. owned about 0.35% of OPKO Health worth $4,552,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after buying an additional 373,032 shares during the period. SG Americas Securities LLC purchased a new stake in OPKO Health during the 1st quarter worth $585,000. Vanguard Group Inc. increased its stake in OPKO Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company's stock worth $48,970,000 after buying an additional 293,740 shares during the period. Bank of America Corp DE increased its stake in OPKO Health by 94.7% during the 4th quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock worth $855,000 after buying an additional 282,844 shares during the period. Finally, Two Sigma Investments LP grew its holdings in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after acquiring an additional 949,671 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This represents a 0.32% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 49.69% of the company's stock.

OPKO Health Stock Performance

Shares of NASDAQ OPK traded up $0.02 during midday trading on Wednesday, hitting $1.38. The company's stock had a trading volume of 1,964,404 shares, compared to its average volume of 2,161,245. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.04. The firm's fifty day moving average price is $1.35 and its 200-day moving average price is $1.45. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The firm has a market cap of $1.10 billion, a P/E ratio of -5.52 and a beta of 1.40.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. During the same period last year, the firm posted ($0.01) earnings per share. The company's quarterly revenue was down 13.9% on a year-over-year basis. On average, sell-side analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on OPK. LADENBURG THALM/SH SH raised shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. Zacks Research raised shares of OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.